Shire Patent Infringement Suit Over Adderall XR Triggers 30-Month Stay
This article was originally published in The Pink Sheet Daily
Executive Summary
Stay of FDA action on Andrx' ANDA will extend beyond Barr's entry, Shire says.
You may also be interested in...
Shire Confident Of Vyvanse Approval, Despite Second ‘Approvable’ Letter
Adderall XR follow-on still slated for Q2 2007 launch.
Shire Confident Of Vyvanse Approval, Despite Second ‘Approvable’ Letter
Adderall XR follow-on still slated for Q2 2007 launch.
Shire Expects Next-Generation Adderall XR Approval Following DEA Scheduling
"Approvable" letter from FDA says marketing approval of NRP-104 is contingent upon final scheduling by DEA.